| Literature DB >> 36266275 |
Mads Grønborg1, Ulrik de Lichtenberg1,2, Christian T Madsen3, Jan C Refsgaard1,4, Felix G Teufel1, Sonny K Kjærulff1,4, Zhe Wang5, Guangjun Meng5,6, Carsten Jessen1, Petteri Heljo1, Qunfeng Jiang5,7, Xin Zhao5, Bo Wu5,8, Xueping Zhou5,9, Yang Tang5,10, Jacob F Jeppesen1, Christian D Kelstrup1, Stephen T Buckley1, Søren Tullin1,11, Jan Nygaard-Jensen1,11, Xiaoli Chen5, Fang Zhang5,12, Jesper V Olsen13, Dan Han5.
Abstract
Peptides play important roles in regulating biological processes and form the basis of a multiplicity of therapeutic drugs. To date, only about 300 peptides in human have confirmed bioactivity, although tens of thousands have been reported in the literature. The majority of these are inactive degradation products of endogenous proteins and peptides, presenting a needle-in-a-haystack problem of identifying the most promising candidate peptides from large-scale peptidomics experiments to test for bioactivity. To address this challenge, we conducted a comprehensive analysis of the mammalian peptidome across seven tissues in four different mouse strains and used the data to train a machine learning model that predicts hundreds of peptide candidates based on patterns in the mass spectrometry data. We provide in silico validation examples and experimental confirmation of bioactivity for two peptides, demonstrating the utility of this resource for discovering lead peptides for further characterization and therapeutic development.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36266275 PMCID: PMC9584923 DOI: 10.1038/s41467-022-34031-z
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 17.694